During the Health System Executive Summit, Candy Tsourounis, PharmD, and Elise Wozniak, PharmD got candid about the barriers and financial risk surrounding this innovative therapy.
News|Articles|April 21, 2026
4 takeaways from UnitedHealth Group’s first quarter earnings call
Author(s)Denise Myshko
In an earning call, UnitedHealth Group executives, including CEO Stephen Hemsley, discussed the company’s strategy, which is focused value-based care, its Medicare Advantage programs transparency, AI and its transparency efforts.
Advertisement
Advertisement
UnitedHealth Group
Related to this article
Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
Research findings presented at CHEST meeting show COPD hospital readmission drops with discharge checklists and navigation. Other research suggests targeting readmission prevention efforts on patents discharged to post-acute facilities.
As the pharmacist pipeline tightens, leaders from UC Davis Health, UCSF Health, and Sutter Health say financial sustainability now depends as much on capacity as on cost.
GLP-1 use in adults 65 and older with MASLD was linked to a 45% lower risk of death, and a 28% lower risk of hepatic decompensation, a new Houston Methodist Research Institute study shows.
New data from Sutter Health suggest the real gap in GLP-1 access is physician awareness, not insurance coverage — and fixing it closed outcome disparities across every racial and ethnic group.
Research findings presented at the CHEST meeting show that false positives may make patients more adherent to screening. Qualitative research shows that patients want more explanation and results communicated verbally.
David Chen, PharmD, explains how physician-led formulary decisions — not rebates — power Kaiser Permanente’s biosimilar strategy, and why he thinks other health systems could do the same.
Advertisement
Advertisement